Uffe Klausen1*
Staffan Holmberg2,3
Morten Orebo Holmström1,4Nicolai Grønne Dahlager Jørgensen1Jacob Handlos Grauslund1,4
Inge Marie Svane1,5Mads Hald Andersen1,6- 1Center for Cancer Immune Therapy, Herlev Hospital, Department of Hematology and Oncology, Herlev, Denmark
- 2Department of Hematology, Herlev Hospital, Herlev, Denmark
- 3Division of Immunology - T cells & Cancer, DTU Nanotech, Technical University of Denmark, Lyngby, Denmark
- 4Department of Hematology, Zealand University Hospital, Roskilde, Denmark
- 5Institute for Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 6Institute for Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
Peptides vaccination is an interesting approach to activate T-cells toward desired antigens in hematological malignancies. In addition to classical tumor associated antigens, such as cancer testis antigens, new potential targets for peptide vaccination comprise neo-antigens including JAK2 and CALR mutations, and antigens from immune regulatory proteins in the tumor microenvironment such as programmed death 1 ligands (PD-L1 and PD-L2). Immunosuppressive defenses of tumors are an important challenge to overcome and the T cell suppressive ligands PD-L1 and PD-L2 are often present in tumor microenvironments. Thus, PD-L1 and PD-L2 are interesting targets for peptide vaccines in diseases where the tumor microenvironment is known to play an essential role such as multiple myeloma and follicular lymphoma. In myelodysplastic syndromes the drug azacitidine re-exposes tumor associated antigens, why vaccination with related peptides would be an interesting addition. In myeloproliferative neoplasms the JAK2 and CALR mutations has proven to be immunogenic neo-antigens and thus possible targets for peptide vaccination. In this mini review we summarize the basis for these novel approaches, which has led to the initiation of clinical trials with various peptide vaccines in myelodysplastic syndromes, myeloproliferative neoplasms, multiple myeloma, and follicular lymphoma.
Introduction
Cancer vaccine therapy is based on the principle of activating an immune response toward cancer cells. The concept dates back to the Nineteenth century when William Coley attempted to raise an immune response against cancer by exposing patients to bacterial extracts (1). In the view of modern research standards Coley's results are questionable, but since then the field has evolved immensely and modern therapeutic cancer vaccines induce potent anti-tumor immune responses. The field of therapeutic cancer vaccines involves a variety of methods including cellular vaccines, RNA/DNA based vaccines, viral vaccines, and peptide/protein vaccines described in detail by Gou et al. (2) Peptide vaccines hold the advantage of short production times and easy administration and will be the focus of this review. This method is based on peptides from selected tumor proteins that are injected into patients along with an immune activating adjuvant. After injection, the peptides are processed by antigen presenting cells and presented to T cells in the draining lymph node, as illustrated in Figures 1B,C. T cells recognizing the presented epitopes are primed to recognize cells expressing the target proteins, as these are presenting the epitopes on the cell surface. The vaccine field is fueled by the continuous discovery of targetable epitopes. Such epitopes are either neo-antigens, which are formed by somatic mutations that generate a novel mutant antigen, or non-mutated antigens that are overexpressed by the neoplastic cells. Unfortunately, therapeutic cancer vaccination has yet to show significant clinical impact. Limitations to this approach involves a variety of immune escape mechanisms including defected antigen presentation identified in many tumors and T cells unable to find or penetrate the tumors, which might be a minor issue in hematological malignancies as these by nature are less immune restricted than solid tumors (3). Another major limitation is the immunosuppressive mechanisms employed by tumor cells and regulatory cells in the tumor microenvironment (Figure 1A) (2). Immune checkpoints such as the PD-1/PD-L1 pathway inhibit activated T cells and thereby prevent an effective antitumor response. Monoclonal antibodies blocking these pathways known as checkpoint inhibitors allow the activated T cells to function regardless of the suppressive signals from the surroundings. Checkpoint inhibitors have proven effective in both solid and hematological cancers (4). However, not all tumors respond to checkpoint inhibitors and they are associated with serious side effects. Targeting the checkpoints through therapeutic vaccination offers a novel way to directly target regulatory pathways in the tumor microenvironment and potentially modify tolerance to tumor antigens. Like the checkpoint inhibitors the vaccine approach might relieve the immune suppression and potentiate anti-tumor T cell responses, but in addition, the vaccine may recruit activated T cells to the tumor site and promote epitope spreading when the target cells are killed. Addressing the immune regulatory mechanisms is essential to improve the outcomes of peptide vaccination.
Figure 1. Targeting PD-L1 and PD-L2 expressing cells. (A) T cells in the tumor microenvironment often express PD-1 and are vulnerable to stimulation from the ligands PD-L1 or PD-L2 expressed on tumor cells or tumor infiltrating cells such as macrophages or Myeloid-derived suppressor cells (MDSC). (B) Immunogenic peptides derived from the PD-L1 and PD-L2 can be injected in the patients where they are endocytosed and processed by antigen presenting cells (APC). (C) The APCs present the peptides to T cells in the draining lymph node along with co-stimulatory signals, which are necessary for priming and optimal cytotoxicity. (D) Tumor cells, macrophages and MDSCs expressing PD-L1 and PD-L2 also present epitopes derived from these proteins on surface MHC molecules and are vulnerable to primed PD-L1 and PD-L2 specific T cells.
In this mini review we summarize novel strategies to overcome immune suppression and enhance tumor recognition, which have led to clinical trials in myelodysplastic syndrome, myeloproliferative neoplasms, multiple myeloma, and follicular lymphoma.
Targeting Immune Checkpoints in Multiple Myeloma
Multiple myeloma (MM) is a neoplastic disease of plasma cells with hallmarks including hypercalcemia, renal insufficiency, anemia, and bone lesions. In the recent years several new treatment options have become available, which has improved the median survival. However, the disease is still incurable. All cases of MM are preceded by the precursor state monoclonal gammopathy of undetermined significance (MGUS) and some patients progress via an intermediate state termed smoldering multiple myeloma (SMM) (5). Since the majority of genetic mutations are already present in the precursor states, changes in the microenvironment are believed to impact the risk of progression (6). The microenvironment in MM is severely immunosuppressive (7), and decreased humoral and cellular immune responses to viral and neoplastic epitopes in patients with MGUS and SMM are risk factors for progression to MM (8). Progression from MGUS to MM is also correlated to the expression level of the immune checkpoint molecule programmed death ligand 1 (PD-L1) on MM cells (8). PD-L1 interacts with the molecule PD-1 on T cells and serves as a powerful negative regulatory signal, which plays a major role in the normal physiologic maintenance of immune self-tolerance, reviewed in Keir et al (9). In symptomatic MM, T cells and natural killer (NK) cells in the tumor microenvironment display increased amounts of PD-1, and MM-cells, osteoclasts and dendritic cells demonstrate elevated levels of PD-L1 (10–16). One study showed that PD-L1 is variably expressed on clonal plasma cells in newly diagnosed MM patients (17). The PD-1/PD-L1 pathway not only promotes the progression of myeloma indirectly by immune evasion; bone marrow stromal cells induce myeloma cells to express PD-L1, which results in increased tumor cell proliferation and reduced susceptibility to anti-myeloma chemotherapy (18). Extramedullary plasmacytomas from patients with late stage MM are characterized by increased expression of PD-L1 (19). Furthermore, the level of PD-1 on T cells is inversely correlated with overall survival (20). Additionally, patients display increased levels of PD-L1 on myeloma cells at relapse or when refractory to treatment, and is associated with an aggressive disease phenotype (21). Increased numbers of T cells with upregulated PD-1 and an exhausted immune phenotype is identified in patients that relapse after high-dose chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HDT-ASCT), indicating that the PD-1/PD-L1 axis could be an important determinant of early relapse after HDT-ASCT (22).
We have characterized T cells in cancer patients that are able to recognize peptides derived from PD-L1 protein, and demonstrated that specific T cells isolated and expanded from these patients are able to recognize and kill PD-L1 expressing cells (23, 24). PD-L1 specific T cells target both tumor cells as well as PD-L1 expressing cells in the microenvironment (Figure 1D) (25, 26). Furthermore, stimulation of T cell cultures with PD-L1 peptide was in vitro shown to boost the antineoplastic effect of a dendritic cell (DC)-vaccine (27). This effect is likely based on the ability of PD-L1 specific T cells to kill regulatory PD-L1 positive cells in the cell culture, consequently leading to an attenuated immune regulation.
Based on these observations, we have initiated a phase I study testing safety and efficacy of PD-L1 peptide vaccination as a monotherapy consolidation after HDT-ASCT in patients with MM. Furthermore, we are initiating a vaccination study with PD-L1 peptide for patients with SMM. Of note, monotherapy with the anti PD-1 monoclonal antibody (mAb) nivolumab did not show effect in MM (28). Several combination studies of PD-1 specific mAbs have been halted by the Food and Drug Administration (FDA) due to increased mortality in the experimental arms. The halt has recently been lifted on several studies, but the difficulties using anti-PD-1 mAbs for MM underline the need for development of alternative approaches to target the PD-1/PD-L1 pathway in MM.
Targeting Immune Checkpoints in Follicular Lymphoma
Follicular lymphoma (FL) is an incurable disease characterized by waxing and waning courses of the disease and is often monitored without the need for active treatment. Over time the disease expands and there is a substantial risk of transformation to more aggressive lymphomas. The mainstay treatment is chemotherapy and anti-CD20 mAbs. Since FL is an indolent disease, it is believed to be ideal for vaccination therapy, which has been explored in FL, in the form of anti-idiotype cancer vaccines. So far this approach has failed to show clinical benefit when tested against placebo or chemotherapy in phase III trials (29–31). There are many possible reasons for the lack of success in these trials, but the immunosuppressive microenvironment in FL is a probable explanation. A gene expression study in FL revealed that the gene signature from regulatory immune cells was an independent adverse prognostic factor (32). Another study looked at the gene expression of specific immunosuppressive proteins in the microenvironment and found 24 out of 54 to be upregulated in FL compared to healthy tissue (33). PD-L1 and programmed death ligand 2 (PD-L2) were among the upregulated genes, which also was confirmed by immunohistochemistry. Both PD-L1 and PD-L2 play a role in immune suppression and contribute to the reduced cytotoxic potential of effector T cells (34). In FL PD-L1 expression has also been identified on tumor-infiltrating macrophages (35).
The clinical relevance of the PD-1 pathway was investigated in a phase I checkpoint inhibition trial, where heavily treated FL patients were treated with the PD-1 blocking mAb Nivolumab as monotherapy. 4 out of 10 had an objective response and one achieved complete response (CR) (28), indicating that the PD-1/Ligand pathway could be important for successful vaccination therapy. As mentioned above, cytotoxic PD-L1 specific T cells can be expanded in cultures by stimulation with PD-L1 derived peptides. Likewise, immunogenic PD-L2 epitopes have been identified, and spontaneous immune responses against these epitopes have been observed in cancer patients (36). Additionally, PD-L2 specific T cells are cytotoxic to PD-L2 expressing tumor cells. Based on these findings and additional unpublished data, we are conducting a phase I vaccination trial with PD-L1 and PD-L2 derived peptides in relapsed FL as maintenance after chemotherapy (NCT03381768). This vaccine is primarily targeting the PD-L1 and PD-L2 positive tumor infiltrating macrophages known to stimulate tumor vascularization and moreover have been correlated with disease transformation and poor prognosis (37, 38). Furthermore, the macrophages seem to have a lymphoma propagating role by secretion of IL15 (39). Thus, by targeting PD-L1 and PD-L2 expressing tumor- and regulatory cells in FL, we hope to shift the immunological balance toward tumor elimination.
Targeting Cancer Testis Antigens in Myelodysplastic Syndrome
Myelodysplastic syndrome (MDS) is a malignant disorder characterized by clonal expansion of mutated myeloid precursor cells, resulting in an accumulation of blasts in the bone marrow and cytopenia due to ineffective hematopoiesis. MDS responds poorly to chemotherapy, and the only curative treatment is allogeneic HSCT (allo-HSCT), which most often is not feasible due to the high treatment related mortality. Hypomethylating agents (HMA), such as azacitidine or decitabine, are standard therapies for patients with high-risk MDS, who are not eligible for an allo-HSCT. HMAs works by incorporating themselves into the DNA by competitively binding at cytidine nucleotides. After DNA incorporation, the drug covalently attaches to DNA methyltransferase (DNMT), resulting in a loss of methylation and subsequently re-expression of the affected genes as the cell divides (Figure 2A) (40).
Figure 2. Expression of antigens in myelodysplastic syndrome and myeloproliferative neoplasms. (A) DNA methyltransferase (DNMT) add methyl (M) groups to parts of the genome to prevent transcription. The drug azacitidine binds to cytidine nucleotides where it covalently attaches to DNMT to prevent further methylation. This results in the transcription of otherwise suppressed genes such as cancer testis antigens (CTA) and retroviral DNA. The CTA are processed as proteins and presented by MHC molecules on the cell surface, while the double stranded RNA (dsRNA) trigger intracellular pattern recognition receptors causing inflammation and increased MHC expression. (B) Mutations in the JAK2 gene results in the substitution of valine (V) to phenylalanine (F) in position 617 of the JAK2 protein. This results in the generation of a mutant antigen. Likewise, the CALR exon 9 mutations generate a novel mutant C-terminus in the CALR protein, thus generating several mutant antigens.
Several possible synergies may be achieved by combining HMA with therapeutic cancer vaccination. Firstly, a group of genes called cancer testis antigens (CTA) not usually expressed in healthy tissue due to gene methylation, has been found to be expressed by neoplastic cells (41). Treatment with HMA has shown to enhance the expression of CTA (42–46), while not affecting the expression in healthy tissue (47–49). Since healthy cells do not express CTA, the immune system has not developed central tolerance to these antigens, and they can be exploited as targets for immunotherapy. Secondly, HMA induces transcription of DNA from endogenous retroviruses resulting in an inflammatory response in tumor cells (50–53). Double stranded RNA from the viruses activates viral defense pathways, which causes the cell to produce interferon's and upregulate HLA class I molecules (Figure 2A). This inflammatory response makes the cancer cells more susceptible to immune mediated killing. Thirdly, the bone marrow of MDS patients has an immunosuppressive microenvironment with an increased amount of myeloid derived suppressor cells (MDSCs) (54). HMA has been shown to deplete MDSCs (55), thus potentially making it easier for T cells to exert an effective tumor-specific immune response.
Vaccination against CTA as monotherapy has previously been tested in many cancer types with varying success (56–58), and trials combining CTA-derived epitopes with HMA are now emerging (59, 60). In NCT02750995 we are targeting four CTAs (NY-ESO-1, PRAME, MAGE-A3, and WT-1) in combination with azacitidine, and another study is investigating a dendritic cell directed vaccine targeting NY-ESO-1 in combination with decitabine and a PD-1 checkpoint inhibitor (NCT03358719). The use of checkpoint inhibitors is expected to further enhance the potency of the combination therapy, since HMA also induces upregulation of PD-L1 on tumor cells and PD-1 on T cells (61, 87).
Targeting Neo-Antigens in Myeloproliferative Neoplasms
Chronic myeloproliferative neoplasms (MPN) are cancer diseases of the hematopoietic stem cells of the bone marrow and are characterized by an increased production of peripheral blood cells. MPNs display a very homogenic mutational landscape, as 50% of patients harbor the Janus Kinase 2 (JAK2)V617F driver mutation (62, 63), and 20–25% have a driver mutation in exon 9 of the calreticulin (CALR) gene (64, 65). Recently, both of these mutations were shown to be targets of specific T cells (Figure 2B) (66–68). These findings have opened an avenue for therapeutic cancer vaccination with peptides derived from the JAK2- or CALR-mutations for patients with MPN. However, MPN-patients display several immune-regulatory mechanisms that may attenuate the tumor specific immune response induced by vaccination. Wang et al. showed that patients with MPN have increased numbers of MDSC in peripheral blood, and that mononuclear cells from MPN-patients express increased amounts of the immunoregulatory enzyme arginase-1 compared to healthy donors (69). Additionally, MDSCs from MPN patients are more suppressive to T cells compared to MDSCs from healthy donors. Prestipino and colleagues recently showed that the JAK2V617F-mutation enhances PD-L1 expression in mutant cells through activation of STAT3 and STAT5 (70). As described above, both arginase-I and PD-L1 are targets of specific T cells (23, 24, 71), and the immune mediated killing of arginase-I and PD-L1 expressing cells is believed to enhance the tumor specific immune response (72). Recently, strong and frequent spontaneous T-cell responses against both PD-L1 and arginase-1 were detected in patients with MPN (73, 74). We hypothesize that enhancing these already existing anti-regulatory T-cell responses through therapeutic cancer vaccination with arginase-I and PD-L1 derived epitopes can boost the neo-antigen specific immune response induced by vaccination with JAK2/CALR-mutant epitopes. This method of combinatorial cancer vaccination targeting both driver mutations and immunoregulation could potentially break the immune evasion leading to anti-tumor immunity and clinical effect. Another means to enhance the anti-tumor immune response would be to combine JAK2/CALR-vaccines with PD-1 specific mAbs, as treatment with these drugs have been shown to enhance the amount of neo-antigen specific T cells in peripheral blood (75).
Apart from the obvious combination of JAK2/CALR mutant vaccines with immune checkpoint blocking antibodies, the combination of vaccines with interferon-alpha (IFN-α) is a most interesting option. IFN-α is a potent immunostimulatory cytokine and has been used for years for the treatment of MPN (76). IFN-α has been shown to induce complete hematological responses and major molecular remissions in a substantial proportion of patients (77–79). Concurrently, treatment with IFN-α induces marked alterations in immune cell subsets and in the expression of HLA-related genes (80–83), and the mechanism beyond the clinical effect of IFN-α is believed to rely partially on the induction of an anti-tumor immune response (84). Previous reports on therapeutic cancer vaccination in other malignancies have underscored the importance of a low tumor burden at the time of vaccine initiation in order to obtain a proper clinical response (85). As IFN-α is the only drug, which is able to reduce the tumor burden in a substantial part of the patients, it is most apparent to reduce the tumor burden with IFN-α, and after attainment of a major molecular remission, initiate therapeutic cancer vaccination against the targets described above. This could hopefully eradicate the malignant clone and ultimately cure the patient. However, as exposure of cells to interferon increases the expression of PD-L1 on the exposed cells it could be worthwhile to explore the combination of neo-antigen vaccines and IFN-α with either PD-1 blocking mAbs and/or PD-L1 vaccine in order to counteract the increased amounts of PD-1 ligands induced by IFN-α treatment (86).
Conclusion
The trials described above represent novel approaches to overcome some of the challenges in peptide vaccination including the suppressive mechanisms protecting the tumor cells from an effective anti-tumor immune response. Targeting the immune checkpoints such as the PD-1 ligands or other immune suppressive molecules such as arginase-1 could shift the immunological balance in the tumor microenvironment and ultimately induce an adequate anti-tumor immune response—a strategy that is currently being explored in FL and MM. Combining this approach with tumor specific antigens such as the neoantigens described in MPN could further enhance the anti-tumor response. Finally, combining vaccination against shared antigens, such as CTA, with HMA treatment in MDS is a promising approach to increase immunogenicity of the malignant cells. If the peptide vaccines prove safe and ultimately effective, they will become welcome additions to the toxic treatment options currently available for patients with hematological cancers.
Ethics Statement
All undergoing studies mentioned in the review are approved by the ethical committee of the capital region of Denmark and conducted according to national ethical guidelines and the Helsinki declaration.
Author Contributions
MA, IS, and UK contributed to the conception and design of the review. UK wrote the first draft of the manuscript and provided the figures. SH, MH, NJ, and JG wrote sections of the manuscript. All authors contributed to manuscript revision, read and approved the submitted version.
Funding
Funding for the trials has been granted by Herlev Hospital, the Danish Cancer Society and the Independent Research Fund Denmark.
Conflict of Interest Statement
MA and MH have filed a patent application on the JAK2 and CALR mutations for therapeutic cancer vaccination. MA has filed patent applications on the use of PD-L1, PD-L2, and arginase-1 for therapeutic cancer vaccines. The rights of the patents have been transferred to the Capital Region and Zealand Region according to Danish law on inventions made at public research institutions. The capital region has licensed some of these patents to the company IO Biotech ApS. MA is a shareholder and board member of the IO Biotech ApS, which has the purpose of developing immune-modulating vaccines for cancer treatment.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. McCarthy EF. The toxins of William, B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J. (2006) 26:154–8.
2. Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang X-Y. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. (2013) 119:421–75. doi: 10.1016/B978-0-12-407190-2.00007-1
3. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. (2015) 35:S185–98. doi: 10.1016/J.SEMCANCER.2015.03.004
4. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science (2018) 359:1350–5. doi: 10.1126/science.aar4060
5. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 113:5412–7. doi: 10.1182/blood-2008-12-194241
6. Dhodapkar MV. MGUS to myeloma : a mysterious gammopathy of underexplored significance. Blood (2016) 128:2599–607. doi: 10.1182/blood-2016-09-692954
7. Guillerey C, Nakamura K, Vuckovic S, Hill GR, Smyth MJ. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cell Mol Life Sci. (2016) 73:1569–89. doi: 10.1007/s00018-016-2135-z
8. Dhodapkar MV, Sexton R, Das R, Dhodapkar KM, Zhang L, Sundaram R, et al. Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood (2015) 126:2475–8. doi: 10.1182/blood-2015-03-632919
9. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. (2008) 26:677–704. doi: 10.1146/annurev.immunol.26.021607.090331
10. An G, Acharya C, Feng X, Wen K, Zhong M, Zhang L, et al. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood (2016) 128:1590–603. doi: 10.1182/blood-2016-03-707547
11. Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect : a therapeutic target for CT-011, a novel monoclonal anti – PD-1 antibody. Blood (2010) 116:2286–94. doi: 10.1182/blood-2010-02-271874
12. Hallett WHD, Jing W, Drobyski WR, Johnson BD. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant. (2011) 17:1133–45. doi: 10.1016/j.bbmt.2011.03.011
13. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood (2007) 110:296–304. doi: 10.1182/blood-2006-10-051482
14. Ray A, Das DS, Song Y, Richardson P, Munshi NC, Chauhan D, et al. Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia (2015) 29:1441–4. doi: 10.1038/leu.2015.11
15. Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. (2013) 19:3640–8. doi: 10.1158/1078-0432.CCR-13-0282
16. Sponaas AM, Moharrami NN, Feyzi E, Standal T, Rustad EH, Waage A, et al. PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy. PLoS ONE (2015) 10:e0139867. doi: 10.1371/journal.pone.0139867
17. Paiva B, Azpilikueta A, Puig N, Ocio EM, Sharma R, Oyajobi BO, et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia (2015) 29:2110–3. doi: 10.1038/leu.2015.79
18. Ishibashi M, Tamura H, Sunakawa M, Kondo-Onodera A, Okuyama N, Hamada Y, et al. Myeloma drug resistance induced by binding of myeloma B7-H1 (PD-L1) to PD-1. Cancer Immunol Res. (2016) 4:779–88. doi: 10.1158/2326-6066.CIR-15-0296
19. Crescenzi A, Annibali O, Bianchi A, Pagano A, Donati M, Grifoni A, et al. PD-1/PD-L1 expression in extra-medullary lesions of multiple myeloma. Leuk Res. (2016) 49:98–101. doi: 10.1016/j.leukres.2016.09.008
20. Gasmi B, Smith E, Dogan A, Hsu M, Devlin S, Pichardo J, et al. Presence of PD-1 expressing T cells predicts for inferior overall survival in newly diagnosed multiple myeloma. Blood (2015) 126:1785.
21. Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia (2013) 27:464–72. doi: 10.1038/leu.2012.213
22. Chung DJ, Pronschinske KB, Shyer JA, Sharma S, Leung S, Curran SA, et al. T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res. (2016) 4:61–71. doi: 10.1158/2326-6066.CIR-15-0055
23. Munir S, Andersen GH, Met Ö, Donia M, Frøsig TM, Larsen SK, et al. HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res. (2013) 73:1764–76. doi: 10.1158/0008-5472.CAN-12-3507
24. Munir S, Andersen GH, Svane IM, Andersen MH. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells. Oncoimmunology (2013) 2:e23991. doi: 10.4161/onci.23991
25. Ahmad SM, Larsen SK, Svane IM, Andersen MH. Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. Leukemia (2014) 28:236–8. doi: 10.1038/leu.2013.261
26. Ahmad SM, Svane IM, Andersen MH. The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity. Blood Cancer J. (2014) 4:e230. doi: 10.1038/bcj.2014.50
27. Munir Ahmad S, Martinenaite E, Hansen M, Junker N, Borch TH, Met Ö, et al. PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. Oncoimmunology (2016) 5:e1202391. doi: 10.1080/2162402X.2016.1202391
28. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood (2014) 124:A291. doi: 10.1200/JCO.2015.65.9789
29. Lacy MQ, Mandrekar S, Dispenzieri A, Hayman S, Kumar S, Buadi F, et al. Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am J Hematol. (2009) 84:799–802. doi: 10.1002/ajh.21560
30. Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, et al. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J Clin Oncol. (2014) 32:1797–803. doi: 10.1200/JCO.2012.43.9273
31. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. (2011) 29:2787–94. doi: 10.1200/JCO.2010.33.3005
32. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. (2004) 351:2159–69. doi: 10.1056/NEJMoa041869
33. Laurent C, Charmpi K, Gravelle P, Tosolini M, Franchet C, Ysebaert L, et al. Several immune escape patterns in non-Hodgkin's lymphomas. Oncoimmunology (2015) 4:e1026530. doi: 10.1080/2162402X.2015.1026530
34. Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, et al. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood (2013) 121:1367–76. doi: 10.1182/blood-2012-04-421826
35. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. (2011) 17:4232–44. doi: 10.1158/1078-0432.CCR-10-2660
36. Ahmad SM, Martinenaite E, Holmström M, Jørgensen MA, Met Ö, Nastasi C, et al. The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy. Oncoimmunology (2017) 7:e1390641. doi: 10.1080/2162402X.2017.1390641
37. Clear AJ, Lee AM, Calaminici M, Ramsay AG, Morris KJ, Hallam S, et al. Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. Blood (2010) 115:5053–6. doi: 10.1182/blood-2009-11-253260
38. Farinha P, Kyle AH, Minchinton AI, Connors JM, Karsan A, Gascoyne RD. Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica (2010) 95:2157–60. doi: 10.3324/haematol.2009.021766
39. Epron G, Ame-Thomas P, Le Priol J, Pangault C, Dulong J, Lamy T, et al. Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling. Leukemia (2012) 26:139–48. doi: 10.1038/leu.2011.179
40. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer (2008) 123:8–13. doi: 10.1002/ijc.23607
41. Salmaninejad A, Zamani MR, Pourvahedi M, Golchehre Z, Hosseini Bereshneh A, Rezaei N. Cancer/Testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol Invest. (2016) 45:619–40. doi: 10.1080/08820139.2016.1197241
42. Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, Jäger E, et al. The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res. (2010) 34:899–905. doi: 10.1016/j.leukres.2010.02.004
43. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood (2010) 116:1908–18. doi: 10.1182/blood-2009-11-249474
44. Qiu X, Hother C, Ralfkiær UM, Søgaard A, Lu Q, Workman CT, et al. Equitoxic doses of 5-Azacytidine and 5-Aza-2′Deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. PLoS ONE (2010) 5:e12994. doi: 10.1371/journal.pone.0012994
45. Siebenkäs C, Chiappinelli KB, Guzzetta AA, Sharma A, Jeschke J, Vatapalli R, et al. Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. PLoS ONE (2017) 12:e0179501. doi: 10.1371/journal.pone.0179501
46. Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Blagitko-Dorfs N, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget (2016) 7:12840–56. doi: 10.18632/oncotarget.7326
47. Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mol Pharmacol. (2004) 65:18–27. doi: 10.1124/mol.65.1.18
48. Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-Aza-2′-deoxycytidine. Cancer Res. (2002) 62:961–6.
49. Negrotto S, Ng KP, Jankowska AM, Bodo J, Gopalan B, Guinta K, et al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia (2012) 26:244–54. doi: 10.1038/leu.2011.207
50. Brocks D, Schmidt CR, Daskalakis M, Jang HS, Shah NM, Li D, et al. DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats. Nat Genet. (2017) 49:1052–60. doi: 10.1038/ng.3889
51. Chiappinelli KB, Strissel PL, Desrichard A, Chan TA, Baylin SB, Correspondence S. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell (2015) 162:974–86. doi: 10.1016/j.cell.2015.07.011
52. Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell (2015) 162:961–73. doi: 10.1016/j.cell.2015.07.056
53. Tobiasson M, Abdulkadir H, Lennartsson A, Katayama S, Marabita F, De Paepe A, et al. Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease. Oncotarget (2017) 8:28812–25. doi: 10.18632/oncotarget.15807
54. Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest. (2013) 123:4595–611. doi: 10.1172/JCI67580.miRNA-146a
55. Zhou J, Yao Y, Shen Q, Li G, Hu L, Zhang X. Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells. J Cancer Res Clin Oncol. (2017) 143:1371–80. doi: 10.1007/s00432-017-2394-6
56. Baumgaertner P, Costa Nunes C, Cachot A, Maby-El Hajjami H, Cagnon L, Braun M, et al. Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope. Oncoimmunology (2016) 5:e1216290. doi: 10.1080/2162402X.2016.1216290
57. Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. (2018) 2:224–34. doi: 10.1182/bloodadvances.2017014175
58. Ueda Y, Ogura M, Miyakoshi S, Suzuki T, Heike Y, Tagashira S, et al. Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome. Cancer Sci. (2017) 108:2445–53. doi: 10.1111/cas.13409
59. Griffiths EA, Srivastava P, Matsuzaki J, Brumberger Z, Wang ES, Kocent J, et al. NY-ESO-1 vaccination in combination with decitabine induces antigen-specific T-lymphocyte responses in patients with myelodysplastic syndrome. Clin Cancer Res. (2017) 24:1019–29. doi: 10.1158/1078-0432.CCR-17-1792
60. Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan JE, Cheerva AC, et al. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother. (2015) 64:1251–60. doi: 10.1007/s00262-015-1731-3
61. Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng Q-R, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia (2014) 28:1280–8. doi: 10.1038/leu.2013.355
62. Kralovics R, Passamonti F, Buser AAS, Teo S-SS-S, Tiedt R, Passweg JRJ, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. (2005) 352:1779–90. doi: 10.1056/NEJMoa051113
63. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 7:387–97. doi: 10.1016/j.ccr.2005.03.023
64. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. (2013) 369:2379–90. doi: 10.1056/NEJMoa1311347
65. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. (2013) 369:2391–405. doi: 10.1056/NEJMoa1312542
66. Holmstrom MO, Riley CH, Svane IM, Hasselbalch HC, Andersen MH, Holmström MO, et al. The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms. Leukemia (2016) 30:2413–6. doi: 10.1038/leu.2016.233
67. Holmström MO, Hjortsø MD, Ahmad SM, Met Ö, Martinenaite E, Riley C, et al. The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms. Leukemia (2017) 31:495–8. doi: 10.1038/leu.2016.290
68. Holmström MO, Martinenaite E, Ahmad SM, Met Ö, Friese C, Kjær L, et al. The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia (2018) 32:429–37. doi: 10.1038/leu.2017.214
69. Wang JC, Kundra A, Andrei M, Baptiste S, Chen C, Wong C. Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm. Leuk Res. (2016) 43:39–43. doi: 10.1016/j.leukres.2016.02.004
70. Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, et al. Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci. Transl. Med. (2018) 10:1–13. doi: 10.1126/SCITRANSLMED.AAM7729
71. Martinenaite E, Mortensen REJ, Hansen M, Orebo Holmström M, Munir Ahmad S, Grønne Dahlager Jørgensen N, et al. Frequent adaptive immune responses against arginase-1. Oncoimmunology (2017) 7:e1404215. doi: 10.1080/2162402X.2017.1404215
72. Andersen MH. Anti-regulatory T cells. Semin Immunopathol. (2017) 39:317–26. doi: 10.1007/s00281-016-0593-x
73. Holmström MO, Riley CH, Skov V, Svane IM, Hasselbalch HC, Andersen MH. Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response. Oncoimmunology (2018) 7:e1433521. doi: 10.1080/2162402X.2018.1433521
74. Jørgensen MA, Holmström MO, Martinenaite E, Riley CH, Hasselbalch HC, Andersen MH. Spontaneous T-cell responses against Arginase-1 in chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation. Oncoimmunology (2018) 7:e1468957. doi: 10.1080/2162402X.2018.1468957
75. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. (2018) 378:1976–86. doi: 10.1056/NEJMoa1716078
76. Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythaemia vera, essential thrombocytemia and myelofibrosis. Exp. Hematol. (2013) 6:1–10. doi: 10.1586/ehm.12.69
77. Kjær L, Cordua S, Holmström MO, Thomassen M, Kruse TA, Pallisgaard N, et al. Differential dynamics of CALR mutant allele burden in myeloproliferative neoplasms during interferon alfa treatment. PLoS ONE (2016) 11:e0165336. doi: 10.1371/journal.pone.0165336
78. Stauffer Larsen T, Iversen KF, Hansen E, Mathiasen AB, Marcher C, Frederiksen M, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res. (2013) 37:1041–5. doi: 10.1016/j.leukres.2013.06.012
79. Verger E, Cassinat B, Dosquet C, Giraudier S. Clinical and molecular response to interferon- a therapy in essential thrombocythemia patients with CALR mutations. Blood (2015) 126:2585–92. doi: 10.1182/blood-2015-07-659060
80. Riley CH, Jensen MK, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, et al. Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α. Blood (2011) 118:2170–3. doi: 10.1182/blood-2011-03-340992
81. Riley CH, Hansen M, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, et al. Expansion of circulating CD56(bright) natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α. Eur J Haematol. (2015) 94:227–34. doi: 10.1111/ejh.12420
82. Riley CH, Brimnes MK, Hansen M, Jensen MK, Hasselbalch HC, Kjaer L, et al. Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera. Eur. J. Haematol. (2016) 97:83–92. doi: 10.1111/ejh.12687
83. Skov V, Riley CH, Thomassen M, Kjær L, Stauffer Larsen T, Bjerrum OW, et al. The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms. Leuk Lymphoma (2017) 58:1914–21. doi: 10.1080/10428194.2016.1262032
84. Kiladjian J-J, Giraudier S, Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia (2015) 30:1–6. doi: 10.1038/leu.2015.326
85. Melief CJM, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 8:351–60. doi: 10.1038/nrc2373
86. Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. (2016) 375:1767–78. doi: 10.1056/NEJMra1514296
Keywords: peptide vaccination, follicular lymphoma, multiple myeloma, myeloproliferative neoplasms, myelodysplastic syndrome, PD-1, cancer testis antigen, neo-antigens
Citation: Klausen U, Holmberg S, Holmström MO, Jørgensen NGD, Grauslund JH, Svane IM and Andersen MH (2018) Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies. Front. Immunol. 9:2264. doi: 10.3389/fimmu.2018.02264
Received: 29 June 2018; Accepted: 11 September 2018;
Published: 01 October 2018.
Edited by:
An Maria Theophiel Van Nuffel, Anticancer Fund, BelgiumReviewed by:
Cristina Maccalli, Sidra Medical and Research Center, QatarSaid Dermime, National Center for Cancer Care and Research, Qatar
Copyright © 2018 Klausen, Holmberg, Holmström, Jørgensen, Grauslund, Svane and Andersen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Uffe Klausen, uffe.klausen@regionh.dk